VMD vs. PNTG, CDNA, FLGT, FTRE, CSTL, OMDA, AUNA, SBC, INNV, and TALK
Should you be buying Viemed Healthcare stock or one of its competitors? The main competitors of Viemed Healthcare include The Pennant Group (PNTG), CareDx (CDNA), Fulgent Genetics (FLGT), Fortrea (FTRE), Castle Biosciences (CSTL), Omada Health (OMDA), Auna (AUNA), SBC Medical Group (SBC), InnovAge (INNV), and Talkspace (TALK). These companies are all part of the "healthcare" industry.
Viemed Healthcare vs. Its Competitors
The Pennant Group (NASDAQ:PNTG) and Viemed Healthcare (NASDAQ:VMD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.
Viemed Healthcare has a net margin of 5.80% compared to The Pennant Group's net margin of 3.36%. Viemed Healthcare's return on equity of 10.38% beat The Pennant Group's return on equity.
In the previous week, The Pennant Group had 5 more articles in the media than Viemed Healthcare. MarketBeat recorded 13 mentions for The Pennant Group and 8 mentions for Viemed Healthcare. Viemed Healthcare's average media sentiment score of 0.80 beat The Pennant Group's score of 0.76 indicating that Viemed Healthcare is being referred to more favorably in the news media.
The Pennant Group has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500. Comparatively, Viemed Healthcare has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.
The Pennant Group has higher revenue and earnings than Viemed Healthcare. Viemed Healthcare is trading at a lower price-to-earnings ratio than The Pennant Group, indicating that it is currently the more affordable of the two stocks.
The Pennant Group currently has a consensus price target of $33.40, indicating a potential upside of 32.22%. Given The Pennant Group's stronger consensus rating and higher probable upside, equities analysts clearly believe The Pennant Group is more favorable than Viemed Healthcare.
85.9% of The Pennant Group shares are owned by institutional investors. Comparatively, 74.2% of Viemed Healthcare shares are owned by institutional investors. 5.4% of The Pennant Group shares are owned by insiders. Comparatively, 20.0% of Viemed Healthcare shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
The Pennant Group beats Viemed Healthcare on 11 of the 16 factors compared between the two stocks.
Get Viemed Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for VMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viemed Healthcare Competitors List
Related Companies and Tools
This page (NASDAQ:VMD) was last updated on 8/15/2025 by MarketBeat.com Staff
MarketBeat All Access